America’s biopharmaceutical companies continue to voice the dangers of current proposals in Washington that would allow the government to set prices for medicines. While it’s being called government “negotiation,” it really is government price setting, and it would have significant ramifications for research and development efforts that fuel innovation, sacrificing by a conservative estimate more than 60 treatments over the next three decades.
